A carregar...
Antiphospholipid antibodies during 6-month treatment with infliximab: A preliminary report
BACKGROUND: The introduction of tumor necrosis factor (TNF) antagonists (adalimumab, infliximab, and etanercept) was a major advance and was highly important and beneficial in most rheumatoid arthritis (RA) patients. The adverse effects of this treatment are infrequent, but include opportunistic int...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Scientific Literature, Inc.
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4109570/ https://ncbi.nlm.nih.gov/pubmed/25027437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.890270 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|